Michael J. Fox Foundation Awards $3.8 Million to Drive Nine Industry Partnerships for Pre-Clinical Parkinson's Drug Development
While MJFF accepts applications from industry under all of its programs, the Therapeutics Development Initiative (TDI) ó first launched in 2006 ó is the Foundationís only industry-exclusive funding stream. It is a key element of MJFFís strategy to Ďde-riskí preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinsonís therapeutic development and helping push the most promising research to the next stage.
Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundationís Searchable Database of Funded Grants. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchersí agreement to make the results of their work available to the Parkinsonís research community.
†Pharmacodynamics of ReS9-S7, a first-in-class, disease-modifying drug candidate for treatment of Parkinsonís disease
Gerard Griffioen, PhD, NV reMYND, Leuven, Belgium
Exploring curcumin and curcumin derivatives as putative epigenetic targets of histone deacetylase (HDAC) inhibition in Parkinsonís disease
Lawrence Helson, MD, Sign Path Pharma, Inc., Quakertown, Pennsylvania
Assessment of the therapeutic efficacy of progranulin in a sub-chronic animal model of Parkinsonís disease
Denis Kay, PhD, Neurodyn, Inc., Charlottetown, Prince Edward Island, Canada
Validation of LRRK2 as a drug target for treatment of Parkinsonís disease using antisense technology
Alejandro Lloret, PhD, Isis Pharmaceuticals, Inc., Carlsbad, California
Optimising lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates
Alastair D. Reith, PhD, GlaxoSmithKline, United Kingdom
A novel approach to characterize the distribution of a potentially therapeutic dominant-negative inhibitor of tumor necrosis factor in pre-clinical models of PD, and predict the scalability for an effective delivery of therapy in the human brain
Lisa Lynn Shafer, PhD, Medtronic Neuromodulation, Minneapolis, Minnesota
Pre-clinical development of a Parkinsonís disease therapy using a glucagon-like peptide (GLP-1) receptor agonist
Kevin Tomaselli, PhD, Amylin Pharmaceuticals, Inc., San Diego, California
Symptomatic Approaches/Complications of Treatment
Effect of novel neuronal nicotonic receptor compounds on treatment of levodopa-induced dyskinesia in Parkinsonís disease
Kristen Jordan, PhD, Targacept, Winston-Salem, North Carolina
Optimization of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinsonís disease
Patrick Little, PhD, Adolor Corporation, Exton, Pennsylvania
TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $16.5 million total for 33 industry-led projects under the initiative.